TY - JOUR
T1 - Improving Continuous Glucose Monitoring Uptake in Underserved Youth with Type 1 Diabetes
T2 - The IMPACT Study
AU - Lin, Tyger
AU - Manfredo, Jacquelyn A.
AU - Illesca, Nicole
AU - Abiola, Kai
AU - Hwang, Nearry
AU - Salsberg, Sandra
AU - Akhtar, Yasmin
AU - Mathioudakis, Nestoras
AU - Brown, Elizabeth A.
AU - Wolf, Risa M.
N1 - Funding Information:
R.M.W. received an investigator-initiated research grant from Dexcom to support this study. R.M.W. reports receiving research grants from Boehringer Ingelheim outside the submitted study.
Publisher Copyright:
© Copyright 2023, Mary Ann Liebert, Inc., publishers 2023.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Background: Continuous glucose monitoring (CGM) improves glycemic control. Less than half of youth with type 1 diabetes (T1D) use CGM, with disparities among minority and low-income youth. The aim of this study was to determine if trial CGM use increases uptake of personal CGM. Methods: T1D youth were provided sample CGM placement at the point of care, with CGM education and app setup. Follow-up calls at 5 and 10 days assessed CGM data, and desire to continue using CGM. Follow-up at 3-6 months recorded CGM use, CGM data, and A1c. Participants completed surveys at enrollment, 10 days, and 3 months. Differences were assessed between baseline and follow-up. Results: Of the 26 enrolled participants with T1D, 15 were CGM naive, and 11 were prior CGM users. The mean age was 14.1 ± 2.9 years, 65% male, 42% were Black, 12% were Hispanic, 65% were on public insurance, and 43% had household income of <$50,000. The median duration of diabetes was 4.6 years (interquartile range 2.4-7.7), mean baseline A1c was 10.7% ± 2.4%. After trial CGM use, 85% of participants reported wanting personal CGM, and at 3-6 months follow-up 76% had obtained one and 43% were using a personal CGM. There were no improvements in A1C or time in range, but participants reported an increase in the perceived benefits of CGM usage (4.0 vs. 4.3, p = 0.03). Conclusions: Placing a sample CGM at the point of care can improve uptake of personal CGM and may help mitigate disparities in CGM use in minority and underserved youth. Long-term studies are needed to determine how similar interventions impact glycemic control and patient outcomes. ClinicalTrials.gov:
AB - Background: Continuous glucose monitoring (CGM) improves glycemic control. Less than half of youth with type 1 diabetes (T1D) use CGM, with disparities among minority and low-income youth. The aim of this study was to determine if trial CGM use increases uptake of personal CGM. Methods: T1D youth were provided sample CGM placement at the point of care, with CGM education and app setup. Follow-up calls at 5 and 10 days assessed CGM data, and desire to continue using CGM. Follow-up at 3-6 months recorded CGM use, CGM data, and A1c. Participants completed surveys at enrollment, 10 days, and 3 months. Differences were assessed between baseline and follow-up. Results: Of the 26 enrolled participants with T1D, 15 were CGM naive, and 11 were prior CGM users. The mean age was 14.1 ± 2.9 years, 65% male, 42% were Black, 12% were Hispanic, 65% were on public insurance, and 43% had household income of <$50,000. The median duration of diabetes was 4.6 years (interquartile range 2.4-7.7), mean baseline A1c was 10.7% ± 2.4%. After trial CGM use, 85% of participants reported wanting personal CGM, and at 3-6 months follow-up 76% had obtained one and 43% were using a personal CGM. There were no improvements in A1C or time in range, but participants reported an increase in the perceived benefits of CGM usage (4.0 vs. 4.3, p = 0.03). Conclusions: Placing a sample CGM at the point of care can improve uptake of personal CGM and may help mitigate disparities in CGM use in minority and underserved youth. Long-term studies are needed to determine how similar interventions impact glycemic control and patient outcomes. ClinicalTrials.gov:
KW - Barriers
KW - Continuous glucose monitors
KW - Glycemic control
KW - Type 1 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85142044736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142044736&partnerID=8YFLogxK
U2 - 10.1089/dia.2022.0347
DO - 10.1089/dia.2022.0347
M3 - Article
C2 - 36223197
AN - SCOPUS:85142044736
SN - 1520-9156
VL - 25
SP - 13
EP - 19
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 1
ER -